Chemours Company (The) (NYSE:CC) Stake Held by James Investment Research Inc.

James Investment Research Inc. held its stake in Chemours Company (The) (NYSE:CC) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,125 shares of the specialty chemicals company’s stock at the end of the second quarter. James Investment Research Inc.’s holdings in Chemours Company (The) were worth $498,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in Chemours Company (The) by 48,297.2% in the first quarter. BlackRock Inc. now owns 19,160,930 shares of the specialty chemicals company’s stock valued at $737,696,000 after buying an additional 19,121,339 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Chemours Company (The) by 1.2% in the first quarter. Vanguard Group Inc. now owns 18,773,273 shares of the specialty chemicals company’s stock worth $722,771,000 after buying an additional 215,900 shares in the last quarter. FMR LLC boosted its stake in shares of Chemours Company (The) by 36.6% in the first quarter. FMR LLC now owns 14,925,373 shares of the specialty chemicals company’s stock worth $574,627,000 after buying an additional 3,998,914 shares in the last quarter. State Street Corp boosted its stake in shares of Chemours Company (The) by 35.1% in the first quarter. State Street Corp now owns 5,791,792 shares of the specialty chemicals company’s stock worth $222,987,000 after buying an additional 1,504,657 shares in the last quarter. Finally, Prudential Financial Inc. boosted its stake in shares of Chemours Company (The) by 64.1% in the first quarter. Prudential Financial Inc. now owns 4,473,227 shares of the specialty chemicals company’s stock worth $172,219,000 after buying an additional 1,747,880 shares in the last quarter. 76.51% of the stock is currently owned by institutional investors and hedge funds.

Chemours Company (CC) traded up 2.61% during midday trading on Friday, hitting $46.08. The stock had a trading volume of 1,651,927 shares. The firm has a 50-day moving average of $45.01 and a 200 day moving average of $38.80. The firm has a market capitalization of $8.52 billion, a P/E ratio of 30.16 and a beta of 3.63. Chemours Company has a 52-week low of $12.16 and a 52-week high of $51.51.

Chemours Company (The) (NYSE:CC) last issued its earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter last year, the company posted $0.27 earnings per share. The firm’s revenue was up 14.8% compared to the same quarter last year. On average, equities analysts forecast that Chemours Company will post $3.51 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Thursday, August 17th will be issued a $0.03 dividend. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $0.12 dividend on an annualized basis and a yield of 0.26%. Chemours Company (The)’s payout ratio is 8.11%.

WARNING: This news story was originally published by BNB Daily and is owned by of BNB Daily. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.baseball-news-blog.com/2017/08/19/james-investment-research-inc-continues-to-hold-stake-in-chemours-company-the-nysecc-updated-updated-updated.html.

A number of brokerages have recently commented on CC. UBS AG reissued a “sell” rating and issued a $36.00 price target (up from $35.00) on shares of Chemours Company (The) in a research report on Wednesday, June 14th. Susquehanna Bancshares Inc boosted their price target on Chemours Company (The) from $45.00 to $55.00 and gave the stock a “positive” rating in a research report on Monday, May 15th. Zacks Investment Research lowered shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. J P Morgan Chase & Co boosted their price objective on shares of Chemours Company (The) to $55.00 and gave the stock an “overweight” rating in a report on Friday, August 4th. Finally, Jefferies Group LLC boosted their price objective on shares of Chemours Company (The) to $60.00 and gave the stock a “buy” rating in a report on Thursday, August 3rd. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Chemours Company (The) currently has a consensus rating of “Buy” and a consensus price target of $51.50.

In other Chemours Company (The) news, insider E Bryan Snell sold 10,000 shares of Chemours Company (The) stock in a transaction on Friday, August 11th. The shares were sold at an average price of $46.24, for a total value of $462,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Amy Trojanowski sold 2,500 shares of Chemours Company (The) stock in a transaction on Friday, August 11th. The shares were sold at an average price of $46.03, for a total transaction of $115,075.00. The disclosure for this sale can be found here. Insiders sold 31,536 shares of company stock valued at $1,365,946 in the last ninety days. 1.14% of the stock is owned by corporate insiders.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply